ライフサイエンスコーパス: dyspnoea

1 e throat, and headache) and some vice versa (dyspnoea).

2 d events (one with hypokalaemia and one with dyspnoea).

3 ore subjective symptoms, such as fatigue and dyspnoea.

4 ion, and arterial blood gases do not measure dyspnoea.

5 linically characterised by fever, cough, and dyspnoea.

6 death was attributed to both pneumonitis and dyspnoea.

7 ected patients with cancer for palliation of dyspnoea.

8 xamethasone versus placebo on cancer-related dyspnoea.

9 me to deterioration in cough, chest pain, or dyspnoea.

10 may lead to a greater perceived intensity of dyspnoea.

11 and may be a contributing factor to exercise dyspnoea.

12 contribute significantly to the sensation of dyspnoea.

13 ich may be a contributing factor to exercise dyspnoea.

14 tent chest pain, palpitations and exertional dyspnoea.

15 atistically significant, effect on decreased dyspnoea.

16 iovascular diseases, referred for exertional dyspnoea.

17 lower asthma severity measured by report of dyspnoea.

18 tigue (0.75, 0.46-1.24), shortness of breath/dyspnoea (0.52, 0.28-0.93), breast symptoms (0.59, 0.28-

19 ted mean changes 1.1, 95% CI -1.89 to 4.11), dyspnoea (1.6, -0.58 to 3.87), chest pain (0.4, -2.13 to

20 The most common serious adverse event was dyspnoea (16 [6%] and 15 [5%] in the dovitinib and soraf

21 , and anaemia (5 [5%]), sepsis (2 [2%]), and dyspnoea (2 [2%]) with BAT.

22 I 1.2-2.9]), chronic phlegm (2.0 [1.3-3.0]), dyspnoea (2.3 [1.5-3.5]), asthmatic attacks (3.7 [2.2-6.

23 relation to treatment) were fatigue (3; 6%), dyspnoea (2; 4%), and headache (2; 4%).

24 hypertension (47 [17%]), fatigue (24 [8%]), dyspnoea (21 [7%]), and palmar-plantar erythrodysaesthes

25 12 [2%]), pneumonia (24 [5%] vs five [1%]), dyspnoea (22 [4%] vs nine [2%]), asthenia (27 [5%] vs 17

26 of 292 patients), acneiform rash (31 [11%]), dyspnoea (29 [10%]), and decreased neutrophil count (28

27 tide group vs 14 [3%] in the placebo group), dyspnoea (29 [3%] vs 13 [3%]), and metastases to central

28 ] vs 43 [9%]), fatigue (31 [7%] vs 35 [8%]), dyspnoea (29 [6%] vs ten [2%]), decreased lymphocyte cou

29 vs one [<1%] patient in the placebo group), dyspnoea (29 [8%] vs 24 [13%]), and colitis (24 [6%] vs

30 s 0.7 [-1.91 to 3.30] in the placebo group), dyspnoea (3.1 [1.75 to 4.36] vs 1.4 [-0.51 to 3.34]), ch

31 aminotransferase (240 mg daily) and grade 4 dyspnoea (300 mg daily).

32 s in the placebo group; the most common were dyspnoea (34 [9%] patients in the tremelimumab group vs

33 group vs 25 [8%] in the placebo group]) and dyspnoea (35 [11%] vs 45 [14%]).

34 t (28 [10%]), and with pemetrexed alone were dyspnoea (35 [12%] of 289 patients), decreased neutrophi

35 eater than 2% frequency with tecemotide were dyspnoea (49 [5%] of 1024 patients in the tecemotide gro

36 % to 12.7%)), fatigue (5.4% (1.2% to 9.5%)), dyspnoea (7.8% (5.2% to 10.4%)), and reduced concentrati

37 onse was independently associated with worse dyspnoea (adjusted beta for Modified Medical Research Co

38 naria tenuis with a history of urticaria and dyspnoea after drinking beer and a weak skin reactivity

39 esenting to emergency departments (EDs) with dyspnoea and are a valuable adjunct to clinical manageme

40 reported symptoms were urticaria, rhinitis, dyspnoea and cough.

41 plain the effects on exacerbation frequency, dyspnoea and exercise capacity.

42 eletal muscle dysfunction-a primary cause of dyspnoea and exercise intolerance in patients with heart

43 Key facets of dyspnoea and exercise intolerance include skeletal and r

44 acterized by pulmonary vascular remodelling, dyspnoea and exercise intolerance.

45 respect to chest tightness during exercise, dyspnoea and gender.

46 nto two categories: to improve symptoms (ie, dyspnoea and health status) and to decrease future risk

47 All treatments produced improvements in dyspnoea and health-related quality of life; we noted no

48 We also found that the incidence of dyspnoea and hiccup and the fatigue scores, all of which

49 , tiotropium reduces exacerbation frequency, dyspnoea and improves exercise capacity.

50 ts, aged 18-80 years, with cough, wheeze, or dyspnoea and less than 20% bronchodilator reversibility

51 nts who reported fewer respiratory symptoms (dyspnoea and night-time awakenings) were grouped into on

52 ppy hypoxia', in which patient complaints of dyspnoea and observable signs of respiratory distress ar

53 ohort 2 died due to adverse events, one from dyspnoea and one from multiorgan failure, but neither wa

54 xin was associated with favourable relief of dyspnoea and other clinical outcomes, with acceptable sa

55 Patients presenting with exertional dyspnoea and signs of diastolic dysfunction (E/e'>8, lef

56 diagnoses including non-specific chest pain, dyspnoea and syncope (1368 [6%] deaths), and respiratory

57 ad dose-limiting toxicities (one had grade 3 dyspnoea and the other had grade 2 fluid overload), thus

58 sed by variable airflow obstruction, causing dyspnoea and wheezing.

59 mesothelioma commonly present with fatigue, dyspnoea and/or cough caused by pleural effusion, pain a

60 evalence over time for 18/53 symptoms (e.g., dyspnoea), and an increasing prevalence over time for 8/

61 han 40, these adverse events included cough, dyspnoea, and abnormal respiration.

62 loped a simplified ADO index (including age, dyspnoea, and airflow obstruction) from the Swiss cohort

63 le functioning, social functioning, fatigue, dyspnoea, and appetite loss on the EORTC QLQ-C30 and pai

64 common prespecified PRO concepts were cough, dyspnoea, and chest pain.

65 luding body-mass index, airflow obstruction, dyspnoea, and exercise capacity) was an important contri

66 -life subscales (physical functioning, pain, dyspnoea, and global health status) at any of the assess

67 non-specific symptoms including chest pain, dyspnoea, and palpitations, it often mimics more common

68 f they had life-limiting illness, refractory dyspnoea, and partial pressure of oxygen in arterial blo

69 3 or 4 adverse events were worsening of IPF, dyspnoea, and pneumonia.

70 that are associated with excessive coughing, dyspnoea, and reflex bronchospasm and secretions.

71 dial perfusion imaging for chest pain and/or dyspnoea at Brigham and Women's Hospital (Boston, MA, US

72 iopulmonary exercise testing for unexplained dyspnoea at Mayo Clinic in 2006-18 were studied.

73 verse events occurred in 164 (44%) patients, dyspnoea being the most common (18 patients [5%]).

74 ncreased alanine aminotransferase, rash, and dyspnoea being the most common.

75 will improve management of problems such as dyspnoea, cachexia, and haemoptysis for patients across

76 Dyspnoea can progress to orthopnoea (with no rales on lu

77 ion of adenosine (Ado) to patients can cause dyspnoea, chest discomfort and bronchoconstriction.

78 Typical symptoms include dyspnoea, chest pain, palpitations, and syncope.

79 , had a severe follow-up reaction (involving dyspnoea) compared with 12% initially.

80 tudy, 234 patients with acute heart failure, dyspnoea, congestion on chest radiograph, and increased

81 All patients had dyspnoea, congestion on chest radiograph, increased brai

82 F)-like phenotype marked by cardiac wasting, dyspnoea, congestion, and/or physical dysfunction.

83 anagement of key symptoms, focusing on pain, dyspnoea, constipation, and anorexia-cachexia syndromes.

84 tress failure induces HAPE, characterized by dyspnoea, cough and exercise intolerance.

85 eporting cardiopulmonary symptoms (including dyspnoea, cough, and chest pain) and any long COVID symp

86 Patients presented with dyspnoea, cough, and were found to be hypoxaemic with bi

87 air the quality of life of patients, causing dyspnoea, cough, haemoptysis and pain, potentially dimin

88 both the simtuzumab and placebo groups were dyspnoea, cough, upper respiratory tract infection, and

89 sequences including acid-base dysregulation, dyspnoea, decreased cerebral blood flow and accelerated

90 hree [4%]), and fatigue, maculopapular rash, dyspnoea, decreased lymphocyte count, and decreased neut

91 Dyspnoea, defined as a sensation of an uncomfortable awa

92 Two patients (0.3%) developed worsening dyspnoea during the 30 day post-operative period, but te

93 12 of 97 participants had chest tightness or dyspnoea during treatment with lumacaftor alone.

94 (nine [5%]), thrombocytopenia (eight [4%]), dyspnoea (eight [4%]), and myelodysplastic syndromes (si

95 eased lipase concentration (12 [9%] of 137), dyspnoea (eight [6%]), and hypertension (seven [5%]).

96 Serelaxin improved the VAS AUC primary dyspnoea endpoint (448 mm x h, 95% CI 120-775; p=0.007)

97 Ten (83%) patients had dyspnoea, fever, and emesis and nine (75%) had cough.

98 igue (seven [18%] and eight [23%] patients), dyspnoea (five [13%] and seven [20%] patients), and pneu

99 e than one patient in the surgery group were dyspnoea (four [15%] patients), chest pain (four [15%] p

100 re hyponatremia (five [2%] of 240 patients), dyspnoea (four [2%] patients), and pneumonia (four [2%]

101 thological fracture (five [3%] vs two [1%]), dyspnoea (four [2%] vs one [1%]), bone pain (one [1%] vs

102 5 toxicity and one (1%) case each of grade 3 dyspnoea, grade 2 pneumonitis, and grade 2 lung fibrosis

103 erse events were reported by seven patients: dyspnoea, headache, hypertension, intervertebral disc pr

104 s occurred in nine (2%; acute kidney injury, dyspnoea, hepatic failure, hepatitis, neutropenia, pneum

105 5% patients) were fatigue, asthenia, nausea, dyspnoea, hypertension, and headache; and none (>=3% pat

106 diotherapy group (abdominal pain, diarrhoea, dyspnoea, hypokalemia, and respiratory failure), and fou

107 eased neutrophil count (four [2%]), anaemia, dyspnoea, hyponatraemia, increased alanine aminotransfer

108 o [3%]), febrile neutropenia (two [3%]), and dyspnoea, hypoxia, respiratory failure, sinus tachycardi

109 Dyspnoea improved with relaxin 30 microg/kg compared wit

110 oportion of patients with moderate or marked dyspnoea improvement measured by Likert scale during the

111 The primary endpoints evaluating dyspnoea improvement were change from baseline in the vi

112 Dyspnoea in chronic obstructive pulmonary disease (COPD)

113 hin the physiological range had no effect on dyspnoea in healthy older adults.

114 ygen therapy is widely used for treatment of dyspnoea in individuals with life-limiting illness who a

115 ory constraint during submaximal exercise on dyspnoea in older men and women.

116 High-dose dexamethasone did not improve dyspnoea in patients with cancer more effectively than p

117 ds are commonly prescribed for palliation of dyspnoea in patients with cancer, despite scarce evidenc

118 symptomatic benefit for relief of refractory dyspnoea in patients with life-limiting illness compared

119 atients (54%); fatigue in 23 patients (50%); dyspnoea in ten patients (22%); and stomatitis in three

120 n of the composite of cough, chest pain, and dyspnoea in the QLQ-LC13.

121 ne treatment-related death caused by grade 4 dyspnoea (in cohort C).

122 related reaction (in four [2%] patients) and dyspnoea (in two [1%]) occurring in more than one patien

123 mpared with placebo were anxiety, dizziness, dyspnoea, increased alanine aminotransferase, influenza,

124 Patients given bosentan had a reduced Borg dyspnoea index and an improved WHO functional class.

125 .66) and 0.30 (-0.37 to 0.97) for Transition Dyspnoea Index score, and -0.01 (-1.81 to 1.78) and -2.7

126 tionnaire (SGRQ) total score, and Transition Dyspnoea Index using repeated measurements mixed effect

127 moderate or severe exacerbations, Transition Dyspnoea Index, and FEV(1), with former smokers being mo

128 results were observed for FEV(1), Transition Dyspnoea Index, and SGRQ total score; however, the relat

129 anges in cardiopulmonary haemodynamics, Borg dyspnoea index, WHO functional class, and withdrawal due

130 aged 18 years or older, and with an average dyspnoea intensity score on an 11-point numerical rating

131 ditions, women reported significantly higher dyspnoea intensity than men (2.9 +/- 0.9 vs.

132 intensity of exertional breathlessness (i.e. dyspnoea) is higher in older women than in older men, po

133 respiratory failure, respiratory failure and dyspnoea, lung infection, and pneumonitis).

134 sease progression in four (10%) patients and dyspnoea, malignant neoplasm, and sepsis in one (2%) pat

135 aspiration (n=1), rectal haemorrhage (n=1), dyspnoea (n=1), failure to thrive (n=1), and interstitia

136 (n=16 [15%]), thrombocytopenia (n=12 [11%]), dyspnoea (n=3 [3%]), and hypotension (n=3 [3%]) in the B

137 mmonly occurring serious adverse events were dyspnoea (n=3 [5%]), pneumonitis (n=3 [5%]), pericardial

138 Common symptoms included dyspnoea (n=513 [84%]), cough (n=500 [81%]), and wheezin

139 rest/during exercise-stress) and non-cardiac dyspnoea (NCD).

140 (>=3% patients) were hypertension, anaemia, dyspnoea, neutropenia, thrombocytopenia, pneumonia, COVI

141 association with asthma severity (report of dyspnoea, night-time symptoms, rescue medication use, an

142 ripheral neuropathy (44 [8%] vs four [<1%]), dyspnoea (nine [2%] vs 38 [7%]), and thromboembolic even

143 l count decrease (two [1%] vs 12 [17%]), and dyspnoea (nine [6%] vs three [4%]).

144 %] of 88 in the best supportive care group), dyspnoea (none vs two [2%]), anaemia (two [2%] vs none),

145 The mean change in dyspnoea NRS intensity from baseline to day 7 (+/-2 days

146 The primary outcome was change in dyspnoea NRS intensity over the past 24 h from baseline

147 DRB2 gene significantly associated with less dyspnoea (odds ratio (OR) 0.2, 95% confidence interval (

148 PAP results in progressive dyspnoea of insidious onset, hypoxaemic respiratory fail

149 ecorded sign (peripheral oedema) or symptom (dyspnoea) of HF, and whose N-terminal pro-B-type natriur

150 r pressures, cardiorespiratory responses, or dyspnoea on exertion (DOE) in these patients.

151 e [1%]), respiratory failure (one [1%]), and dyspnoea (one [1%]); one death was attributed to both pn

152 metinib group vs none in the placebo group), dyspnoea (one [2%] of 44 patients in the selumetinib gro

153 sentations with a single reported symptom of dyspnoea or confusion were also identified, alongside a

154 vents (three [10%] chest wall pain, two [6%] dyspnoea or cough, and one [3%] fatigue and rib fracture

155 Most individuals present with dyspnoea or evidence of right heart failure.

156 n organ toxicity was pulmonary (grade 3 or 4 dyspnoea or hypoxia including mechanical ventilation), a

157 ne symptom of COPD (cough, sputum, wheezing, dyspnoea, or chest tightness), with at least one of the

158 e pain (ten [9%]), rash (eight [7%]), cough, dyspnoea, or other pulmonary symptoms (five [5%]), fatig

159 Symptoms and clinical signs of AHF (e.g. dyspnoea, orthopnoea, oedema, jugular vein distension, a

160 er in females (p = 0.016), and patients with dyspnoea (p = 0.048), HTN (p = 0.034), immunodeficiency

161 r time to deterioration of cough (p<0.0001), dyspnoea (p=0.049), and pain (p=0.041).

162 ed interstitial lung disease meeting defined dyspnoea, pulmonary function, and high-resolution CT (HR

163 t failure with serelaxin was associated with dyspnoea relief and improvement in other clinical outcom

164 t failure with serelaxin was associated with dyspnoea relief and improvement in other clinical outcom

165 erelaxin-treated patients would have greater dyspnoea relief compared with patients treated with stan

166 ing breathlessness (Medical Research Council dyspnoea scale >/=4) to receive active or placebo NMES,

167 the modified Medical Research Council (mMRC) dyspnoea scale (score 0-1 vs >/=2) and the St George's R

168 d beta for Modified Medical Research Council Dyspnoea Scale 0.12 [95% CI 0.00 to 0.24]; p=0.05), lowe

169 earch Council Dyspnea Scale [mMRCDS]; Cancer Dyspnoea Scale [CDS]), quality of life (Functional Asses

170 ter on the modified Medical Research Council dyspnoea scale.

171 <450 m), and substantial breathlessness (MRC dyspnoea score >/=3).

172 p=0.002), modified Medical Research Council Dyspnoea score (1.32, 1.25-1.39; p<0.0001), daily sputum

173 ix, and patients were stratified by baseline dyspnoea score (4-6 vs 7-10) and study site.

174 ase in the modified Medical Research Council dyspnoea score from baseline.

175 .81 (SD 0.78), mean Medical Research Council dyspnoea score was 1.33 (SD 0.65); 28 (30%) of 95 patien

176 Changes in KCCQ-TSS and CHQ-SAS dyspnoea score were non-significant.

177 etic peptide (NT-proBNP)concentrations, Borg dyspnoea score, health-related quality of life (EQ-5D sc

178 f-Administered Standardized format (CHQ-SAS) dyspnoea score.

179 partate aminotransferase (six [2%] vs none), dyspnoea (six [2%] vs one [1%]), and pleural effusion (s

180 reported in at least 5% of all patients were dyspnoea (ten [7%]), pneumonia (nine [7%]), and hypoxia

181 ring in more than five patients (>/=3%) were dyspnoea (ten patients [5%]), pneumonia (nine [5%]), and

182 mab group vs two [1%] in the placebo group), dyspnoea (three [1%] vs two [1%]); respiratory failure (

183 %] vs 0), syncope (three [12%] vs two [8%]), dyspnoea (three [12%] vs one [4%]), pulmonary embolism (

184 six (7%) were deemed treatment related, with dyspnoea (three [3%]) and pneumonia (two [2%]) reported

185 [8%] of 92 patients), rash (four [4%]), and dyspnoea (three [3%]).

186 , oedema (four [8%] and none, respectively), dyspnoea (three [6%] and two [10%], respectively), and h

187 her toxic effects were fatigue (11 vs 9) and dyspnoea (three vs four).

188 ed in eight (27%) of 26 patients (diarrhoea, dyspnoea, thrombocytopenia, vomiting, urinary tract infe

189 which symptomatic treatment does not control dyspnoea to the patient's satisfaction, sedation is an e

190 anetumab ravtansine: pneumonia (three [2%]), dyspnoea (two [1%]), sepsis (two [1%]), atrial fibrillat

191 ly infusion-related reactions (two [1%]) and dyspnoea (two [1%]).

192 rombocytopenia, abdominal pain, anxiety, and dyspnoea (two [5%] each).

193 fatigue, asthenia, atrial fibrillation, and dyspnoea (two [5%] each); in the placebo group, such eve

194 he most common grade 3-4 adverse events were dyspnoea (two [8%] in the durvalumab-tremelimumab alone

195 on; headache/visual disturbances; chest pain/dyspnoea; vaginal bleeding with abdominal pain; systolic

196 me to deterioration in cough, chest pain, or dyspnoea was not reached (95% CI 10.2 months to not reac

197 straint between conditions, the intensity of dyspnoea was unaffected, independent of sex (P = 0.46).

198 rst, a core symptom set of fever, cough, and dyspnoea, which co-occurred with additional symptoms in

199 ptoms (cough, chest pain, sputum production, dyspnoea) with no worsening in any symptom at 72 h after